The role of B cell-mediated T cell costimulation in the efficacy of the T cell retargeting bispecific antibody BIS20x3

Journal of Immunology

Volumn 173, Issue 10, 2004, Pages 6009-6016

  Stel, Alja J ^a   Kroesen, Bart Jan ^a   Jacobs, Susan ^a   Groen, Herman ^b   De Leij, Lou F M H ^a   Kluin Nelemans, Hanneke C ^a   Withoff, Sebo ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b IQ Products   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIS20X3 ANTIBODY; BISPECIFIC ANTIBODY; CD19 ANTIGEN; CD20 ANTIGEN; CD3 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; RITUXIMAB; UNCLASSIFIED DRUG;

ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CELL INTERACTION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; DRUG TARGETING; HODGKIN DISEASE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; T LYMPHOCYTE ACTIVATION; TRANSACTIVATION;

EID: 8444239638     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.173.10.6009     Document Type: Article

References (51)

1. Maloney, D. G., A. J. Grillo-Lopez, C. A. White, D. Bodkin, R. J. Schilder, J. A. Neidhait, N. Janakiraman, K. A. Foon, T. M. Liles, B. K. Dallaire, et al. 1997. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188.
2. McLaughlin, P., F. B. Hagemeister, and A. J. Grillo-Lopez. 1999. Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin. Oncol. 26:79.
3. Colombat, P., G. Salles, N. Brousse, P. Eftekhari, P. Soubeyran, V. Delwail, E. Deconinck, C. Haioun, C. Foussard, C. Sebban, et al. 2001. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 97:101.
4. McLaughlin, P., A. J. Grillo-Lopez, B. K. Link, R. Levy, M. S. Czuczman, M. E. Williams, M. R. Heyman, I. Bence-Bruckler, C. A. White, F. Cabanillas, et al. 1998. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16:2825.
5. Foran, J. M., R. K. Gupta, D. Cunningham, R. A. Popescu, A. H. Goldstone, I. W. Sweetenham, R. Pettengell, P. W. Johnson, E. Bessell, B. Hancock, et al. 2000. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br. J. Haematol. 109:81.
6. Voso, M. T., G. Pantel, S. Rutella, M. Weis, F. D'Alo, R. Urbano, G. Leone, R. Haas, and S. Hohaus. 2002. Rituximab reduces the number of peripheral blood B-cells in vitro mainly by effector cell-mediated mechanisms. Haematologica 87:918.
7. Flieger, D., S. Renoth, I. Beier, T. Sauerbruch, and I. Schmidt-Wolf. 2000. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cell Immunol. 204:55.
8. Reff, M. E., K. Carner, K. S. Chambers, P. C. Chinn, J. E. Leonard, R. Raab, R. A. Newman, N. Hanna, and D. R. Anderson. 1994. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435.
9. Shan, D., J. A. Ledbetter, and O. W. Press. 2000. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol. Immunother. 48:673.
10. Cragg, M. S., S. M. Morgan, H. T. Chan, B. P. Morgan, A. V. Filatov, P. W. Johnson, R. R. French, and M. I. Glennie. 2003. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 101:1045.
11. Golay, J., L. Zaffaroni, T. Vaccari, M. Lazzari, G. M. Borleri, S. Bernasconi, F. Tedesco, A. Rambaldi, and M. Introna. 2000. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95:3900.
12. Treon, S. P., C. Mitsiades, N. Mitsiades, G. Young, D. Doss, R. Schlossman, and K. C. Anderson. 2001. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J. Immunother. 24:263.
13. Cartron, G., L. Dacheux, G. Salles, P. Solal-Celigny, P. Bardos, P. Colombat, and H. Watier. 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 99:754.
14. Bohen, S. P., O. G. Troyanskaya, O. Alter, R. Warnke, D. Botstein, P. O. Brown, and R. Levy. 2003. Variation in gene expression patterns in follicular lymphoma and the response to rituximab. Proc. Natl. Acad. Sci. USA 100:1926.
15. Clynes, R. A., T. L. Towers, L. G. Presta, and J. V. Ravetch. 2000. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6:443.
16. Withoff, S., M. N. Bijman, A. J. Stel, L. Delahaye, A. Calogero, M. W. Jonge, B. J. Kroesen, and L. Leij. 2001. Characterization of BIS20x3, a bi-specific antibody activating and retargeting T-cells to CD20-positive B-cells. Br. J. Cancer 84:1115.
17. van Lier, R. A., J. H. Boot, E. R. de Groot, and L. A. Aarden. 1987. Induction of T cell proliferation with anti-CD3 switch-variant monoclonal antibodies: effects of heavy chain isotype in monocyte-dependent systems. Eur. J. Immunol. 17:1599.
18. Knapp, W. Leukocyte Typing Conference IV Proceedings. 1990. Oxford University Press, Oxford.
19. Csoka, M., G. Strauss, K. M. Debatin, and G. Moldenhauer. 1996. Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (CALL) blasts by CD3xCD19 bispecific antibody. Leukemia 10:1765.
20. van den Berg, A., B. J. Kroesen, K. Kooistra, D. de Jong, J. Briggs, T. Blokzijl, S. Jacobs, J. Kluiver, A. Diepstra, E. Maggio, and S. Poppema. 2003. High expression of B-cell receptor inducible gene BIC in all subtypes of Hodgkin lymphoma. Genes Chromosomes Cancer 37:20.
21. Calogero, A., G. A. Hospers, K. M. Kruse, P. I. Schrier, N. H. Mulder, E. Hooijberg, and L. F. de Leij. 2000. Retargeting of a T cell line by anti MAGE-3/HLA-A2 αβ TCR gene transfer. Anticancer Res. 20:1793.
22. Lichtenfels, R., W. E. Biddison, H. Schulz, A. B. Vogt, and R. Martin. 1994. CARE-LASS (calcein-release-assay), an improved fluorescence-based test system to measure cytotoxic T lymphocyte activity. J. Immunol. Methods 172:227.
23. Ding, L., and E. M. Shevach. 1996. Activated B cells express CD28/B7-independent costimulatory activity. J. Immunol. 157:1389.
24. I mice. Clin. Immunol. 94:51.
25. Berberich, I., G. L. Shu, and E. A. Clark. 1994. Cross-linking CD40 on B cells rapidly activates nuclear factor-κB. J. Immunol. 153:4357.
26. Li, Q., and I. M. Verma. 2002. NF-κB regulation in the immune system. Nat. Rev. Immunol. 2:725.
27. Zhao, J., G. J. Freeman, G. S. Gray, L. M. Nadler, and L. H. Glimcher. 1996. A cell type-specific enhancer in the human B7.1 gene regulated by NF-κB. J. Exp. Med. 183:777.
28. Xia, Y. F., L. P. Liu, C. P. Zhong, and J. G. Geng. 2001. NF-κB activation for constitutive expression of VCAM-1 and ICAM-1 on B lymphocytes and plasma cells. Biochem. Biophys. Res. Commun. 289:851.
29. Canevari, S., G. Stoter, F. Arienti, G. Bolis, M. I. Colnaghi, E. M. Di Re, A. M. Eggermont, S. H. Goey, J. W. Gratama, and C. H. Lamers. 1995. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J. Natl. Cancer Inst. 87:1463.
30. + advanced prostate cancer. Br. J. Cancer 85:152.
31. Kroesen, B. J., J. Nieken, D. T. Sleijfer, G. Molema, E. G. de Vries, H. J. Groen, W. Helfrich, T. H. The, N. H. Mulder, and L. de Leij. 1997. Approaches to lung cancer treatment using the CD3. X EGP-2-directed bispecific monoclonal antibody BIS-1. Cancer Immunol. Immunother. 45:203.
32. Kroesen, B. J., A. Bakker, R. A. van Lier, H. T. The, and L. de Leij. 1995. Bispecific antibody-mediated target cell-specific costimulation of resting T cells via CD5 and CD28. Cancer Res. 55:4409.
33. Mazzoni, A., D. Mezzanzanica, G. Jung, H. Wolf, M. I. Colnaghi, and S. Canevari. 1996. CD3-CD28 costimulation as a means to avoiding T cell pre-activation in bispecific monoclonal antibody-based treatment of ovarian carcinoma. Cancer Res. 56:5443.
34. Borroto, A., J. Lama, F. Niedergang, A. Dautry-Varsat, B. Alarcon, and A. Alcover. 1999. The CD3ε subunit of the TCR contains endocytosis signals. J. Immunol. 163:25.
35. Brown, J. H., T. S. Jardetzky, J. C. Gorga, L. J. Stern, R. G. Urban, J. L. Strominger, and D. C. Wiley. 1993. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 364:33.
36. Wild, M. K., A. Cambiaggi, M. H. Brown, E. A. Davies, H. Ohno, T. Saito, and P. A. van der Merwe. 1999. Dependence of T cell antigen recognition on the dimensions of an accessory receptor-ligand complex. J. Exp. Med. 190:31.
37. Burroughs, N. J., and C. Wulfing. 2002. Differential segregation in a cell-cell contact interface: the dynamics of the immunological synapse. Biophys. J. 83:1784.
38. Luedtke, R., C. S. Owen, and F. Karush. 1980. Proximity of antibody binding sites studied by fluorescence energy transfer. Biochemistry 19:1182.
39. Leveille, C., R. Al-Daccak, and W. Mourad. 1999. CD20 is physically and functionally coupled to MHC class II and CD40 on human B cell lines. Eur. J. Immunol. 29:65.
40. Leveille, C., J. G. Castaigne, D. Charron, and R. Al Daccak. 2002. MHC class II isotype-specific signaling complex on human B cells. Eur. J. Immunol. 32:2282.
41. Bendall, H. H., M. L. Sikes, D. W. Ballard, and E. M. Oltz. 1999. An intact NF-κB signaling pathway is required for maintenance of mature B cell subsets. Mol. Immunol. 36:187.
42. Leonardi, A., M. Altomonte, M. Maio, G. Tell, A. Bearz, S. Formisano, and C. Pucillo. 1997. Biphasic control of NF-κB activation induced by the triggering of HLA-DR antigens expressed on B cells. Cytokine 9:295.
43. Mathas, S., A. Rickers, K. Bommert, B. Dorken, and M. Y. Mapara. 2000. Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways. Cancer Res. 60:7170.
44. Yamamoto, T., Y. Yamanashi, and K. Toyoshima. 1993. Association of Src-family kinase Lyn with B-cell antigen receptor. Immunol. Rev. 132:187.
45. Ren, C. L., T. Morio, S. M. Fu, and R. S. Geha. 1994. Signal transduction via CD40 involves activation of lyn kinase and phosphatidylinositol-3-kinase, and phosphorylation of phospholipase Cγ 2. J. Exp. Med. 179:673.
46. Deans, J. P., L. Kalt, J. A. Ledbetter, G. L. Schieven, J. B. Bolen, and P. Johnson. 1995. Association of 75/80-kDa phosphoproteins and the tyrosine kinases Lyn, Fyn, and Lck with the B cell molecule CD20: evidence against involvement of the cytoplasmic regions of CD20. J. Biol. Chem. 270:22632.
47. Holland, J., and T. Owens. 1997. Signaling through intercellular adhesion molecule 1 (ICAM-1) in a B cell lymphoma line: the activation of Lyn tyrosine kinase and the mitogen-activated protein kinase pathway. J. Biol. Chem. 272:9108.
48. Uckun, F. M., W. Jaszcz, J. L. Ambras, A. S. Fauci, K. Gajl-Peczalska, C. W. Song, M. R. Wick, D. E. Myers, K. Waddick, and J. A. Ledbetter. 1988. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood 71:13.
49. Pulczynski, S., A. M. Boesen, and O. M. Jensen. 1993. Antibody-induced modulation and intracellular transport of CD10 and CD19 antigens in human B-cell lines: an immunofluorescence and immunoelectron microscopy study. Blood 81:1549.
50. Ma, D., M. R. McDevitt, E. Barendswaard, L. Lai, M. J. Curcio, V. Pellegrini, M. W. Brechbiel, and D. A. Scheinberg. 2002. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies. Leukemia 16:60.
51. Hooijberg, E., P. C. van den Berk, J. J. Sein, J. Wijdenes, A. A. Hart, R. W. de Boer, C. J. Melief, and A. Hekman. 1995. Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model. Cancer Res. 55:840.